Sodium-glucose cotransporter type-2 (SGLT2) inhibitors, as a novel class of hypoglycaemic drugs, are recommended for their favourable effects on patients with type 2 diabetes, especially for the established risk of cardiovascular or renal complications (Chen et al., 2020). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.